07:21 AM EDT, 08/27/2025 (MT Newswires) -- Eli Lilly ( LLY ) said Wednesday that its experimental drug Verzenio, combined with endocrine therapy, showed a statistically significant improvement in overall survival in patients with a certain type of breast cancer, compared to endocrine therapy alone, in a phase 3 study.

The company said a seven-year analysis also demonstrated continued benefits in invasive disease-free survival and distant relapse-free survival, supporting the long-term effectiveness and consistency of the treatment.

Lilly added that, with all patients having either completed or discontinued the two-year Verzenio regimen, the drug's overall safety profile remained unchanged and consistent with previous reports.